SciELO - Scientific Electronic Library Online

 
vol.90Avoidable Hospital Admissions for Heart Failure, SpainMolecular Epidemiology of Bartonella Henselae in Stray and Sheltered Cats of Zaragoza, Spain author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Española de Salud Pública

On-line version ISSN 2173-9110Print version ISSN 1135-5727

Abstract

PUIG-JUNOY, Jaume; RODRIGUEZ-FEIJOO, Santiago; GONZALEZ LOPEZ-VALCARCEL, Beatriz  and  GOMEZ-NAVARRO, Vanessa. Impact of the Pharmaceutical Copayment Reform on the Use of Antidiabetics, Antithrombotics and Drugs for Chronic Airflow Obstructions. Spain. Rev. Esp. Salud Publica [online]. 2016, vol.90, e40009.  Epub Apr 29, 2016. ISSN 2173-9110.

Background:

In 2012 it changed the Spanish legislation regulating the pharmaceutical copayment by the National Health System (NHS). The objective was to know if the Spanish pharmaceutical copayment reform in 2012 has affected drugs consumptions for chronic diseases such as antidiabetics, antithrombotics and agents against obstructive conditions of the respiratory tract.

Methods:

Retrospective longitudinal observational study, using general segmented linear regression models for interrupted time series. The variables analyzed were the number of defined daily doses (DDDs) and the amount corresponding to public funding and not public funding from the NHS since September 2010 to August 2015 (T=60).

Results:

The estimated variation rate of DDDs is negative but decreasing for the three therapeutic subgroups at 6, 12, 24 and 38 months after the intervention: The estimated variation rate of DDDs is negative but decreasing for the most part of the three therapeutic subgroups at 6, 12, 24 and 38 months after the intervention: -0.1% for antidiabetics after 6 months and 0.3% after 38 months; -3.7% for antithrombotics after 6 months and -4.6% after 38 months; -2.7% for asthma and COPD drugs after 6 months and -1.3% after 38 months. A sustained and significant reduction in expenditure was estimated only in the subgroup of asthma and COPD drugs: -5.2% after 6 months, -7.0% after 12 months and after 24 months, and -6.2% after 38 months.

Conclusions:

The pharmaceutical copayment reform of 2012 led to an immediate and significant reduction in the number of DDDs of all three therapeutic subgroups selected in this study. This level effect is not permanent, as it is accompanied by a change in the growth trend in the post-intervention months, which has partly offset the effect on the level.

Keywords : Drug utilization; Interrupted time series analysis; Health care reform; Legislation, pharmacy; Agents, Antidiabetic; Thrombosis; Asthma; Chronic airflow obstruction; Economics, Pharmaceutical.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )